GlaxoSmithKline Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (344)

Latest Posts

About This Stock More About This Stock
Trump + Stocks: The Week In Review
Article By: The Fly
Friday, January 13, 2017 7:44 PM EST
Weekly recap of stocks that are being impacted, or are predicted to be impacted, by the comments, actions and policies of President-elect Trump and his administration.
In this article: GSK, JNJ, JPM, LLY, LMT Also: AXP, NVS, PFE, PNR, ROP, SNY, EHTH, TRS, ENDP, MYL, MNK
Read
E Last London Letter
Article By: Vivian Lewis
Saturday, January 7, 2017 5:03 PM EST
We present some insight on various international stocks on the move.
In this article: ALKS, AZSEY, BABA, BNTC, FAX, FBASF, FCO, GSK, MXCHF, MXE, NOK, SLB, SLFPY, TEVA, VR
Read
Merck (MRK) Does Well In 2016: Reasons For Outperformance
Article By: Zacks Investment Research
Sunday, January 1, 2017 6:09 PM EST
Like many of its peers, Merck is facing generic competition and pricing pressure for some products. Yet, we believe its diversified business model, deep pipeline and strong financial position will continue to help the company navigate tough times.
In this article: AMGN, GSK, MRK, PFE
Read
These 8 Top Dividend Stocks Are Also ADRs - Check Them Out
Article By: Lorimer Wilson
Tuesday, December 13, 2016 8:00 AM EST
An ADR is an issued certificate that represents shares of a foreign stock. They trade on U.S. exchanges and are not subject to foreign taxes or fees. This post identifies and describes 8 of the top dividend ADRs.
In this article: DEO, GSK, NVS, TOT, NSRGY, INFY, TEVA, SIEGY
Read
EC GSK: Robust Pipeline Supports Its 5.5% Dividend Yield
Article By: SureDividend
Sunday, December 4, 2016 11:46 AM EST
GlaxoSmithKline’s broad-based growth is thanks largely to its product innovation. Overall, GlaxoSmithKline spent $3.3B on R&D last year, and has a robust pipeline to show for it.
In this article: GSK Also: PFE
Read

PARTNER HEADLINES

Latest Tweets for $GSK

No tweets yet!